来那度胺联合利妥昔单抗治疗复发难治性B细胞非霍奇金淋巴瘤的疗效观察  

Clinical observation of lenalidomide and rituximab in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma

作　　者：杨宏山[1] 李俊[1] 贾晓艳[1] 刘萍[1] Yang Hongshan;Li Jun;Jia Xiaoyan;Liu Ping(Department of Medical Oncology,Affiliated Xiaogan Hospital of Wuhan University of Science and Technology,Xiaogan 432000,China)

机构地区：[1]武汉科技大学附属孝感医院肿瘤科,432000

出　　处：《国际医药卫生导报》2021年第4期558-560,共3页International Medicine and Health Guidance News

摘　　要：目的观察来那度胺联合利妥昔单抗(R2)的方案治疗复发难治性(R/R)B细胞非霍奇金淋巴瘤(B-NHL)患者的近期疗效和安全性。方法回顾性分析2016年6月至2018年12月于本院肿瘤科就诊的19例R/R B-NHL患者,均接受来那度胺联合利妥昔单抗(R2方案)治疗。R2方案:来那度胺20 mg/d,d1~21,28 d为1周期;利妥昔单抗375 mg/m2,d1、21,每3个周期重新分析评估治疗。患者治疗若得到完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)则继续维持8个周期R2方案。临床观察主要终点为总有效率(ORR,CR+PR),次要终点为1年无进展生存(PFS)时间、总生存率(OS)及药物安全性。结果19例患者中5例获CR,9例获PR,4例获SD,ORR为73.7%;18例患者中位随访时间12个月,1年OS率为89.5%。最常见的不良反应为血液学不良反应,包括血小板减少、中性粒细胞减少、贫血等,大部分患者可以耐受。结论来那度胺联合利妥昔单抗治疗R/R B-NHL患者具有较高反应性,安全性好,能明显延长患者生存期,值得临床进一步研究和应用。Objective To observe and evaluate the efficacy and safety of lenalidomide and rituximab in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma(B-NHL).Methods A total of 19 patients with relapsed/refractory B-NHL in our hospital from June 2016 to December 2018 were retrospectively analyzed.The patients received R2 regimen:oral lenalidomide 20 mg/d d1-21 and rituximab 375 mg/m2of intravenous infusion on d1,21,28 days of each cycle;the efficacy and adverse reactions were evaluated every 3 cycles.After the induction phase,patients achieving complete response(CR),partial response(PR),or stable disease(SD)were given R2 regimen until the end of 8 cycles.The primary clinical endpoint was overall response rate(ORR),and the secondary endpoints were 1-year progression-free survival(PFS),1-year overall survival(OS),and safety.Results In 19 patients,there were 5 cases of CR,9 cases of PR,and 4 cases of SD,with the ORR of 73.7%(14/19).The median follow-up time of 18 patients(5 cases of CR,9 cases of PR,4 cases of SD)was 12 months,1-year OS rate was 89.5%.The most common adverse reactions were hematological adverse reactions,including thrombocytopenia,neutropenia,anemia,which were tolerable for most patients.Conclusion Lenalidomide as an immunomodulator plus rituximab is highly active in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma(B-NHL),and the adverse reactions are mild and well tolerated.This treatment can significantly improve the PFS and OS.

关 键 词：淋巴瘤 非霍奇金 来那度胺 利妥昔单抗 复发 难治 

分 类 号：R733.1[医药卫生—肿瘤]